EUVIMEDEUVIMED entdecken
Fallbericht

B cell-driven reduced-dose rituximab as induction therapy for 2 patients with ANCA-associated renal vasculitis: A case series

Qinglian Wang, Simeng Wang, Xiang Liu, Fajuan Cheng, Ying Xu

Clinical Nephrology · 2025

DOI: 10.5414/cn111372 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Clinical Nephrology, 2025. Verfasst von Qinglian Wang und 4 weiteren Autor:innen. Hauptthemen laut MEDLINE: Rituximab, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, B-Lymphocytes, Immunologic Factors.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RituximabAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisB-LymphocytesImmunologic FactorsGlomerulonephritisHumansMaleFemaleMiddle AgedAgedRemission InductionTreatment OutcomeInduction Chemotherapy

Substanzen

RituximabImmunologic Factors

Zitieren

APA

Wang, Q., Wang, S., Liu, X., Cheng, F., & Xu, Y. (2025). B cell-driven reduced-dose rituximab as induction therapy for 2 patients with ANCA-associated renal vasculitis: A case series. Clinical Nephrology. https://doi.org/10.5414/cn111372

Vancouver

Wang Q, Wang S, Liu X, Cheng F, Xu Y. B cell-driven reduced-dose rituximab as induction therapy for 2 patients with ANCA-associated renal vasculitis: A case series. Clinical Nephrology. 2025. doi:10.5414/cn111372

BibTeX
@article{Wang2025,
  author = {Wang, Qinglian and Wang, Simeng and Liu, Xiang and Cheng, Fajuan and Xu, Ying},
  title = {B cell-driven reduced-dose rituximab as induction therapy for 2 patients with ANCA-associated renal vasculitis: A case series},
  journal = {Clinical Nephrology},
  year = {2025},
  doi = {10.5414/cn111372}
}
Kostenlos starten →